150 results about "Tumor stem cell" patented technology

The invention provides a circulating tumor stem cell detection kit based on magnetic beads and a microfluidic chip. The circulating tumor stem cell detection kit is characterized by comprising a microfluidic chip, at least one immunomagnetic bead, and at least one fluorescent antibody against a tumor stem cell biomarker, wherein the immunomagnetic bead can be specifically bonded with the circulating tumor stem cell and marked with the tumor stem cell biomarker; the microfluidic chip comprises a glass chip base; a microfluidic channel is arranged on the glass chip base; a soft magnetic micro-array is arranged inside the microfluidic channel. By adopting the circulating tumor stem cell detection kit, a plurality of different categories of rare circulating tumor stem cells can be captured and detected by sampling once, and the circulating tumor stem cell detection kit has high sensitivity and specificity, is convenient and fast to operate, can easily collect captured cells, and does not need complicated surface modification processes of a first antibody and a second antibody of the microfluidic channel inside the chip.

Disclosed are methods for isolating cell populations enriched in tumor stem cells (cancer stem cells), and isolated cell populations substantially enriched in cancer stem cells that are tumorigenic in vivo. Also provided are new methods of tumor diagnosis and classification and personalized methods of treatment for subjects with tumors, based on the availability of populations of cancer stem cells derived from the subject's tumor using the disclosed methods.

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.

The invention discloses a reagent for detection of an ROR1 protein in circulating blood and an application thereof, and particularly discloses the reagent for the detection of the ROR1 protein of circulating tumor cells in peripheral blood. The reagent includes an ROR1 antibody, a buffer solution, a marker, a nuclear dye and a lymphocyte identification antibody. A characteristic that ROR1 is only expressed in cancer cells and is not expressed in normal adult tissue cells is utilized, and the reagent is applied to detect the expressed ROR1 protein of the circulating tumor cells or tumor stem cells in the circulating blood, wherein the circulating tumor cells or the tumor stem cells fall off from a primary tumor nidus into the blood; limitations of a traditional method are overcome, and the accuracy and the reliability of the detection of the circulating tumor cells are greatly improved. The reagent can be used for helping detect the tumor cells in the circulating blood of a tumor patient, and is a potential breakthrough point for tumor disease diagnosis, evaluation of therapeutic effects and cancer metastasis monitoring.

Arrangements are provided for destroying tumor cells. According to one aspect, an arrangement includes a device having at least one high-frequency ultrasound generator for generating a thermally active, high-frequency oscillation, a plurality of first low-frequency ultrasound generators for generating a therapeutically active low-frequency oscillation, wherein the first low-frequency ultrasound generators each generate a different frequency, and a control system connected to the high-frequency ultrasound generator and to the first low-frequency ultrasound generators in such a way that the tumor cells are subjected to a high-frequency oscillation acting thermally on the tumor cells and to a low-frequency oscillation. The arrangement further includes a biopsy device having a plurality of individual receivers for tissue samples and a plurality of second low-frequency ultrasound generators operatively connected to the individual receivers for subjecting the tissue samples to an oscillation, wherein oscillations with the same frequency can be generated respectively by first and second low-frequency ultrasound generators.

The invention discloses a cell culture medium. The raw material formula of the cell culture medium comprises 33.33ml of DMEM / High Glucose (DMEM high-glucose culture medium), 66.67ml of HAM'S / F-12 culture medium, 3-5mg / mL of plant-origin recombinant human serum albumin, 100U / ml of penicillin, 100 micrograms / milliliter of streptomycin, 2.5 micrograms / milliliter of amphotericin B, 0.2-0.5 micrograms / milliliter of hydrocortisone, 3-6 micrograms / milliliter of insulin, 6-10ng / ml of cholera toxin B, 9-12ng / ml of human epidermal growth factor EGF, 22-25 micrograms / milliliter of adenine, and 7-9 micromoles / liter of Y-27632. The cell culture medium can be used for culturing primary human tumor cells or tumor stem cells. The cell culture medium is improved; when the cell culture medium is applied to culturing the primary human tumor cells or the tumor stem cells, the cell culture medium is capable of better accelerating the growth of the primary tumor cells and obtaining the human tumor stem cells of a higher ratio.

The invention provides a composition for stimulating an immune response in a patient having different types of cancer including those having adenocarcinoma comprising a combination of allogeneic tumor cells and / or tumor stem cells that are selected on the basis of secreting at least one immunosuppressive agent, e.g., TGF-β, and that are genetically modified to reduce or inhibit the expression of said at least one immunosuppressive agent, e.g., TGF-β, and that collectively express a spectrum of tumor associated antigens representative of colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, and other glandular tissue carcinomas, as well as squamous, melanoma, central nervous system, and lymphomas and a physiologically acceptable carrier. The adenocarcinoma can be, for example, colon, breast, lung, prostate, pancreas, kidney, endometrium, cervix, ovary, thyroid, or other glandular tissue, as well as squamous, melanoma, central nervous system, and lymphomas. The invention also provides a composition containing said combination of allogeneic tumor cells and or tumor stem cells and an allogeneic cell expressing a cytokme or an antibody that inhibits an immune suppressive molecule.

The invention belongs to the technical field of modern biotechnology cell culture. A purpose of the invention is to provide a tumor stem cell suspension culture method, which can be used for culture of tumor cells with different tissue sources, and tumor stem cells obtained through the culture method have characteristics of self-renewal capacity and enrichment. The tumor stem cell suspension culture method comprises: carrying out digestion centrifugation collection on tumor cells requiring culture, adopting PBS to carry out resuspending centrifugation, adding to a prepared suspension culture medium of the invention, carrying out beating-up into a single cell suspension, inoculating into a paved ultra-low absorption culture dish, and carrying out cell culture. The tumor stem cell suspension culture method has the following characteristics that: ball forming rates of various in vitro cultured tumor cells are high, multi-function factors are expressed, the OCT4 proportion and the NANOG proportion are increased, rich and comprehensive experimental materials are provided for tumor stem cell researches, and broad application prospects are provided in basic researches and clinical applications.

The invention discloses a method for in-vitro amplification of tumor stem cells. The method comprises the following steps of carrying out in-vitro three-dimensional culture on tumor cells by an alginate gel support, and adjusting and controlling the rigidity of the alginate gel support by a change of support preparation parameters such as alginate molecular weight, a ratio (GM) of guluronic acid content to mannuronic acid content, a calcium ion concentration and calcification time, so that hardness of an in-vitro matrix in different tumor tissue microenvironments is simulated and in-vitro amplification of tumor stem cells in different tissue is realized. The method can be operated simply, has a low cost and controllable performances, can be industrialized and is a good method for in-vitro amplification on tumor stem cells having different sources.

The invention discloses an anti-hepatoma stem cell monoclonal antibody which is secreted by a mouse hybridoma cell 4P-120 with the collection number of CGMCC No.8800. Proven by experiments, the monoclonal antibody can be specifically combined with hepatoma cells and is capable of specifically recognizing hepatoma tissues, antigens recognized by the monoclonal antibody are highly expressed in cancer tissues of human hepatoma, but are not expressed or slightly expressed in para-carcinoma tissues, and positive-to-negative differentiation and negative-to-positive defifferentiation exist in a cell multiplication process. Compared with cells with low antigen expression, cells with high antigen expression have higher proliferation capability, clone formation capability, balling capability, scratch transfer capability and invasion transfer capability; and the invention provides a functional monoclonal antibody with an application prospect for treating hepatoma with targeted tumor stem cells, and the monoclonal antibody can be used for preparing medicines for treating hepatoma.

The invention provides an application of chlorogenic acid and / or a chlorogenic acid derivative in a tumor stem cell treatment drug and belongs to the technical field of medicine. According to the application of the chlorogenic acid and / or the chlorogenic acid derivative in the tumor stem cell treatment drug, the new application of the chlorogenic acid is provided, and the chlorogenic acid is applied to the tumor stem cell treatment drug, so that the tumor stem cells can be inhibited and killed by the drug and relapse, metastasis and multidrug resistance of tumors are effectively prevented.

The invention belongs to the field of medicine, and particularly relates to the application of 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol to the preparation of an anti-tumor drug. A great number of experiments show that the 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol has the remarkable effect of suppressing malignant tumors such as malignant mammary tumor cells, lymphoma cells and encephaloma cells, and particularly has the effect of killing drug-resistant tumor stem cells such as encephaloma stem cells, so that the 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol can be used for the preparation of the anti-tumor drug, and the drug contains 5alpha-8alpha-ergosterol peroxide-6,22(E)-diene-3beta-alcohol of effective content and a pharmaceutically acceptable carrier.

The embodiment of the invention provides a device and method for targeted ablation of cells, based on a pulsed electric field, a medium and an electronic device. The method includes the steps: generating a high-voltage electric pulse targeting the ablation target cells; applying a high voltage electric pulse to a target cell, wherein a waveform of the high voltage electric pulse and an electric field intensity generated by the high voltage electric pulse are configured according to a component structure parameter and a dielectric parameter of the target cell. The technical proposal of the embodiments of the present invention can repeatedly generate high-voltage electric pulses targeting on tumor stem cells to induce their pyrogenation, and is applied to the tumor stem cells and the escapedhigh-malignancy tumor cells by irreversible electroporation ablation through electrodes and induce their pyrogenation.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method is administered in combination with localized internal ionizing radiation therapy.

The invention relates to an environmental response type anti-tumor nanometer medicine with high medicine loading capacity, a carrier and a preparation method thereof. The nanometer medicine comprisesan amphiphilic polymer carrier and a medicine prodrug; the amphiphilic polymer carrier comprises a hydrophilic segment and a hydrophobic segment which are connected mutually; the hydrophilic segment comprises polyethylene glycol or poly(N-(2-hydroxypropyl)methacrylamide); the hydrophobic segment comprises D-alpha-tocopherol succinate; the medicine prodrug comprises a medicine for treating tumor aswell as a hydrophobic chain segment which is connected with the medicine through a chemical bond; and the hydrophobic chain segment comprises D-alpha-tocopherol succinate. The nanometer medicine hasthe characteristics of high medicine loading capacity, environmental responsiveness and adjustable and controllable grain size, and can achieve the properties that the tumor penetration ability is high, the tumor cell multidrug resistance is achieved, drug-resistant cells are killed in advance, tumor related fibroblast is not killed and tumor stem cells can be killed effectively according to composition of different polymers and the loaded prodrug molecule types.

The invention relates to dendritic cell (DC) tumor vaccine in which a multi-medicine resistance tumor stem cell antigen composition is loaded. The antigen composition loaded in the DC tumor vaccine derives from tumor tissues, and is mainly used for tumor stem cells; and specifically, the tumor tissues are subjected to tumor stem cell primary separation and culture so as to obtain the tumor stem cells, the tumor stem cells are screened by a flow cytometry so as to obtain tumor stem cells with multi-medicine resistance, and finally full cell antigens are prepared.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention relates to an animal model establishment method of human primary skin squamous epithelial cell cancer stem cell. The method comprises the following steps of: preparing collected skin squamous epithelial cell cancer tissue in a clinical case into a single-cell suspension, separating CD31-CD24-CD45-CD61-CD133+tumor stem cell population, suspending and mixing with 1*10<6> human primary mouse embroy fibroblasts and 1*10<6> human primary endothelial cells in matrigel, and then injecting the obtained product into microenvironment through humanized nude mouse subcutaneous tumorigenesis parts. The invention makes further research on molecular biological mechanisms of human skin primary SCC tumour possible.

The invention discloses application of a bifluorescence reporting system in tumor stem cell targeted drug screening and a method thereof. Red and green fluorescence proteins are utilized to respectively mark colony tumor cells and tumor stem cells, and the targeting properties of the drug for the tumor cells and tumor stem cells can be respectively evaluated by using a high-content imaging system. No targeted drug screening methods for tumor stem cells exist at present. The tumor stem cell screening method established by the invention is hopeful to be used for screening novel antineoplastic drugs for tumor stem cells, thereby enhancing the screening effect of the antineoplastic drugs.

The invention provides a dendritic cell carried by a tumor stem cell antigen and subjected to tolerance screening and a preparation method thereof, application of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening in preparing anti-tumor medicament, a kit for preparing the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening, and a vaccine comprising the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening. The dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening and the medicament prepared by an immune composition of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening can kill tumor stem cells causing tumor relapse in vivo and in vitro so as to provide possibility for overcoming the tumor tolerance and radically treating the relapse and transfer of tumor.

The invention provides an enriching and screening method for tumor stem cell. The combination of ball culture and immunomagnetic beads separation method is used for enriching and screening the tumor stem cells, the details are as follows: continuously culturing the tumor cells in a no-serum ball culture medium, using the QPCR method to simultaneously examine the relative levels of tumor stem cell markers, when the expression levels of specific marker is relatively the highest, supplement with immunomagnetic and positive, single or double screening tumor stem cells. The combination of the two screening methods can significantly improve such practical problems as low separation rates, low purity levels and the inconveniences of after application for tumor stem cells.

The invention discloses a compound and application thereof. The compound is the compound shown in the formula (I) or a stereoisomer or a pharmaceutical acceptable salt or solvate or a prodrug of the compound shown in the formula (I). The compound can restrain tumor cell proliferation through the effect RRM2, and restrain tumor stem cell regeneration, thereby being effectively used for preparing medicine for preventing or treating proliferative diseases and particularly anti-cancer medicine.

The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and / or preventing a tumor disease originating from tumor stem cells in a subject. The invention further relates to a new use of fenretinide or bioactive derivatives thereof in combination with other anti-tumor agents, a pharmaceutical composition comprising said fenretinide or bioactive derivatives thereof and at least one additional anti-tumor agent, a method of screening said other anti-tumor agent, a method of eliminating or killing tumor stem cells or particularly hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof, as well as a method of eliminating or killing tumor stem cells and tumor cells derived from tumor stem cells, particularly hematologic tumor stem cells and hematologic tumor cells derived from hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof in combination with other anti-tumor agent(s).

The invention discloses a binding protein of a tumor stem cell marker molecule EpCAM and application of the binding protein. The binding protein is a binding protein formed by one or a combination ofat least two of an NB85 binding protein, an NB143 binding protein, an NB278 binding protein, an NB431 binding protein and an NB589 binding protein. The five binding proteins have the amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 respectively. The invention also discloses the application of the binding protein of the tumor stem cell marker molecule EpCAM in preparation of antitumor drugs. The binding protein provided by the invention is high in structural stability, easy to modify and human-derived, has no immunogenicity in a human body, andcan be better applied to the development of the antitumor drugs.

The invention discloses a magnetic bead immunodetection kit for human colorectal cancer tumor stem cell markers CD44 and CD133, and belongs to the field of immunoglobulin. The kit comprises a Solution I, protease K, a fluorescent CD44 antibody and a magnetic bead CD133 antibody. Technology combining magnetic beads and fluorescence radiation is adopted in the kit for detecting CD44 and CD133 on cytomembranes, thereby saving tedious operation of a flow cytometry. A small quantity of a pathological sample of a patient is added in a kit with the magnetic bead antibody and the fluorescent antibody well prepared and is detected through a fluorescence microscope to get a result. The kit is simple to use, short in detection time and low in cost and has bright application prospects.

The invention discloses a separation method of cancer stem cells. Cancer stem cells and differentiated tumor cells can be separated by different mitochondrial membrane potential of different cells. The cell subgroup with high mitochondrial membrane potential is rich in cancer stem cells, and the cell subgroup with low mitochondrial membrane potential is rich in differentiated tumor cells.